Rhythm Pharmaceuticals (RYTM) PT Lowered to $16 at Goldman Sachs, Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mail
Get Alerts RYTM Hot Sheet
Price: $86.44 --0%
Rating Summary:
19 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Rating Summary:
19 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Join SI Premium – FREE
Goldman Sachs analyst Graig Suvannavejh lowered the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $16.00 (from $23.00) while maintaining a Sell rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Reiterates Perform Rating on Rhythm Pharmaceuticals (RYTM)
- National Stock Exchange of India (NSE:IN) PT Raised to INR1,975 at Macquarie
- Rhythm Pharmaceuticals revises LG Chem license deal, secures $750M loan
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman Sachs, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
